131I-ICF01012 is a quite old product which eventually entered clinical trials in 2018. It is indicated for the diagnostic and treatment of metastasized melanomas. The drug is developed at the Centre Jean Perrin, in Clermont-Ferrand, France.

Target/Mechanism: melanin

Carrier/Ligand: ICF01012

Radiation Type: beta electrons (β)

< Back